[Lysosomal activity in prolactin cells under the effect of a dopamine agonist].
The influence of bromoergocryptine, a dopamine agonist used in clinical praxis, on hormone degradation by the lysosomal system was studied in the pituitary mammotrophs of female rats. Immunocytochemistry of prolactin (protein A-gold technique) combined with the electron-microscopic visualization of the lysosomal system by its non-specific esterase activity (gold thiol-acetic acid method) revealed that bromoergocryptine administration increases the spatial extent of both the lysosomal and the hormone storage compartments with a considerable overlap and interaction between them. This change in compartmentalization may be effective in eliminating hormone excess and preserving cell integrity after release inhibition.
D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology*; D004950:Esterases / Q000378:metabolism*; D005260:Female; D006651:Histocytochemistry; D007118:Immunoassay; D008247:Lysosomes / Q000187:drug effects / Q000201:enzymology*; D010902:Pituitary Gland / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D011388:Prolactin / Q000378:metabolism*; D051381:Rats
D001971:Bromocriptine; D011388:Prolactin; D004950:Esterases
Lysosomale Aktivität in den Prolaktinzellen unter der Wirkung eines Dopamin-Agonisten.